← Back to screener

ARS Pharmaceuticals, Inc. SPRY

Rank #1179 · Nasdaq · $0.3B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
52.6
P/E
42.0
P/B
1.45
ROE
3.5%
Op. Margin
-3.5%
Debt Ratio
41%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆
Good

P/E 42.0x, P/B 1.45x. Ranks in the top 36% of the universe.

Profitability ★★☆☆☆
Weak

ROE 3.5%. Ranks in the top 68% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 41%. Ranks in the top 20% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 297063.3% year over year. Ranks in the top 0% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021–$-0.0B$-0.0B$-0.1B–-20
2022$0.0B$-0.0B$-0.0B$-0.0B-353.3-119
2023$0.0B$-0.0B$-0.0B$-0.0B-2698.8-27
2024$0.0B$-0.1B$-0.1B$0.3B-225066.71
2025$0.1B$-0.0B$0.0B$0.2B-3.541

← See the full screener